Global Antibody Drug Conjugates Market By Drug (ADCETRIS, Kadcyla), Pipeline Analysis (By Phase, Mode of Action, Linker, Technology, and Indication) Outlook 2022

 Table of Contents
1. Analyst View
2. Research Methodology
3. Antibody Drug Conjugate (ADC) - An Introduction
4. ADC Market Outlook to 2022
    4.1 ADCETRIS
          4.1.1 Market Potential
          4.1.2 Market Size and Forecast to 2022
    4.2 Kadcyla
           4.2.1 Market Potential
           4.2.2 Market Size and Forecast to 2022
5. ADC Pipeline Analysis
     5.1 By Companies
            5.1.1 By Clinical Phase
            5.1.2 By Indication
            5.1.3 By Drug
            5.1.4 By Type of Linker
            5.1.5 By Mode of Action
            5.1.6 By Technology
     5.2 By Research Organizations
            5.2.1 By Phase
            5.2.2 By Indication
            5.2.3 By Drug
            5.2.4 By Type of Linker
            5.2.5 By Mode of Action
6. Drivers and Challenges
    6.1 Drivers
         6.1.1 Rising Global Cancer Epidemics
         6.1.2 Advances in Linking Technologies Re-Instills Hope in ADC
         6.1.3 Efforts towards Patent Protection to Drive ADC Market
         6.1.4 Increasing Demand for Antibody Drug Conjugates
    6.2 Challenges
          6.2.1 Production Hurdles and Cost
          6.2.2 Inadequacy of Experienced Manufacturers
          6.2.3 Regulatory Challenges
7. Major Potential ADCs in Pipeline
    7.1 By Companies
          7.1.1 Glembatumumab Vedotin Therapeutics /CDX-011 - Celldex
          7.1.2 Coltuximab Ravtansine/SAR3419 - ImmunoGen Inc.
          7.1.3 Indatuximab Ravtansine/BT-062 - Biotest
          7.1.4 Anti-PSMA ADC Therapeutic - Progenics Pharmaceuticals
          7.1.5 Polatuzumab Vedotin/RG7596 - Roche Genentech
          7.1.6 DMUC-4064A/RG7882 - Roche Genentech
          7.1.7 Mirvetuximab Soravtansine/IMGN853 - ImmunoGen Inc.
          7.1.8 Anti-guanylyl Cyclase C/Anti-GCC ADC - Takeda Millennium
    7.2 By Research
          7.2.1 SGM-101 - SurgiMab in Collaboration with Center for Human Drug Research, Netherlands
          7.2.2 Panitumumab-IRDye800 - Eben Rosenthal/Stanford University
          7.2.3 90Yttrium Ibritumomab Tiuxetan (Zevalin) - Biogen Idec in Collaboration with Soroka University Medical Center
          7.2.4 MOC31-PE - Creative Biolabs in Collaboration with Oslo University Hospital
8. Trends and Developments
    8.1 ADC at the Forefront of Treating Hematological Malignancies
    8.2 ADCs Proving Advantageous for Breast Cancer Patients
9. Strategic Collaborations in the ADC Industry
10. Competitive Assessment
     10.1 Seattle Genetics, Inc.
     10.2 F. Hoffman-La Roche Ltd.
     10.3 ImmunoGen, Inc.
     10.4 Bayer AG
     10.5 Novartis AG
     10.6 Takeda Pharmaceutical Company Limited
     10.7 Immunomedics, Inc.
     10.8 Agensys, Inc.
     10.9 Concortis Biotherapeutics
     10.10 NBE-Therapeutics

List of Tables:

Table 4-1: Potential Patients for ADCETRIS (2012)
Table 4-2: Ongoing Trials for ADCETRIS
Table 4-3: Potential Patients for Kadcyla (2012)
Table 4-4: Ongoing Trials for Kadcyla
Table 5-1: Global - ADC Pipeline of Companies
Table 5-2: Global - ADC Pipeline of Research Organization
Table 9-1: Strategic Collaborations in the ADC Industry (2014-2016)
Table 10-1: Top Companies by ADCs in Pipeline (2016)
Table 10-2: Seattle Genetics, Inc. - ADCs in Pipeline
Table 10-3: Seattle Genetics, Inc. - Key Financials (Million US$), 2013-2015
Table 10-4: Seattle Genetics, Inc. - Strengths and Weaknesses
Table 10-5: F. Hoffman-La Roche Ltd. - ADCs in Pipeline
Table 10-6: F. Hoffman-La Roche Ltd. - Key Financials (Million US$), 2013-2015
Table 10-7: F. Hoffman-La Roche Ltd. - Strengths and Weaknesses
Table 10-8: ImmunoGen, Inc. - ADCs in Pipeline
Table 10-9: ImmunoGen, Inc. - Key Financials (Million US$), 2014-2016
Table 10-10: ImmunoGen, Inc. - Strengths and Weaknesses
Table 10-11: Bayer AG - ADCs in Pipeline
Table 10-12: Bayer AG - Key Financials (Million US$), 2013-2015
Table 10-13: Bayer AG - Strengths and Weaknesses
Table 10-14: Novartis AG - ADCs in Pipeline
Table 10-15: Novartis AG - Key Financials (Million US$), 2014-2016
Table 10-16: Novartis International AG - Strengths and Weaknesses
Table 10-17: Takeda Pharmaceutical Company Limited - ADCs in Pipeline
Table 10-18: Millenium Pharmaceuticals - ADCs in Pipeline
Table 10-19: Takeda Pharmaceutical Company Limited - Key Financials (Million US$), 2014-2016
Table 10-20: Immunomedics, Inc. - ADCs in Pipeline
Table 10-21: Immunomedics, Inc. - Key Financials (Million US$), 2014-2016
Table 10-22: Agensys, Inc. - ADCs in Pipeline
Table 10-23: Astellas Pharma Inc. - Key Financials (Million US$), 2014-2016
Table 10-24: Oxford BioTherapeutics - ADCs in Pipeline
Table 10-25: Concortis Biotherapeutics - ADCs in Pipeline
Table 10-26: NBE-Therapeutics - ADCs in Pipeline 

To request a free sample copy of this report, please complete the form below.

Enter captcha code*

We never share your personal data. Privacy policy